Sufentanil Sublingual Tablet System: from rationale of use to clinical practice

Antonino Giarratano, Andrea Cortegiani, Deni, Paolicchi, Scardino, Rossi, Luca Lorini, Martorano, Coluzzi, Vergari, Leykin, Polati, Antonio Corcione, Rispoli

Research output: Contribution to journalArticlepeer-review

Abstract

The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.
Original languageEnglish
Pages (from-to)11891-11899
Number of pages9
JournalEUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Volume24
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this